Atezolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (CDF Review of TA492) [ID3777]
In development [GID-TA10810] Expected publication date: 22 October 2021
Search results
555 results
-
-
Teduglutide for treating short bowel syndrome [ID3937]
In development [GID-TA10842] Expected publication date: TBC
-
Roxadustat for treating anaemia in people with chronic kidney disease [ID1483]
In development [GID-TA10610] Expected publication date: 02 March 2022
-
Andexanet alfa for reversing anticoagulation [ID1101]
In development [GID-TA10440] Expected publication date: 12 May 2021
-
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies [ID2697]
In development [GID-TA10582] Expected publication date: 26 May 2021
-
Ofatumumab for treating relapsing multiple sclerosis [ID1677]
In development [GID-TA10557] Expected publication date: TBC
-
Secukinumab for treating non-radiographic axial spondyloarthritis [ID1419]
In development [GID-TA10457] Expected publication date: 21 July 2021
-
Ixekizumab for treating axial spondyloarthritis after NSAIDs [ID1532]
In development [GID-TA10458] Expected publication date: 21 July 2021
-
Sapropterin for treating phenylketonuria [ID1475]
In development [GID-TA10378] Expected publication date: 18 August 2021
-
Daratumumab in combination for untreated systemic amyloid light-chain amyloidosis [ID3748]
In development [GID-TA10656] Expected publication date: 02 March 2022
-
Pralsetinib for treating RET-positive advanced non-small-cell lung cancer after platinum-based chemotherapy [ID3875]
In development [GID-TA10770] Expected publication date: TBC
-
Budesonide for treating active eosinophilic oesophagitis [ID1202]
In development [GID-TA10372] Expected publication date: 23 June 2021
-
Dupilumab for treating severe asthma [ID1213]
In development [GID-TA10276] Expected publication date: TBC
-
Atezolizumab monotherapy for untreated PD-L1 positive metastatic non-small-cell lung cancer [ID1678]
In development [GID-TA10587] Expected publication date: 02 June 2021
-
Palforzia for treating peanut allergy [ID1282]
In development [GID-TA10713] Expected publication date: 26 January 2022
-
Drisapersen for the first-line treatment of Duchenne's muscular dystrophy [ID911]
In development [GID-HST10004] Expected publication date: TBC
-
Eteplirsen for treating Duchenne muscular dystrophy [ID1003]
In development [GID-HST10007] Expected publication date: TBC
-
Xpert MTB/RIF assay for the detection of active pulmonary tuberculosis and multi-drug resistant tuberculosis
In development [GID-DT9] Expected publication date: TBC
-
KRAS mutation testing of tumours in adults with metastatic colorectal cancer (discontinued)
In development [GID-DT14] Expected publication date: TBC
-
Multiple myeloma and related disorders - Freelite assays (and alternative technologies identified during scoping) for diagnosis in primary care
In development [GID-DT28] Expected publication date: TBC
-
The Assurance Nasal Alar SpO2 Sensor (discontinued)
In development [GID-MT510] Expected publication date: TBC
-
The IN.PACT drug-coated balloon for peripheral arterial disease (CANCELLED)
In development [GID-MT517] Expected publication date: TBC
-
SeQuent Please Neo balloon catheter for in-stent coronary restenosis - update of MTG1 (discontinued)
In development [GID-MT516] Expected publication date: TBC
-
OraQuick® HCV Rapid Antibody Test (discontinued)
In development [GID-MT117] Expected publication date: TBC
-
Levitronix CentriMag for treatment of refractory cardiogenic shock or severe cardiopulmonary insufficiency (discontinued)
In development [GID-MT130] Expected publication date: TBC
-
Clinitek Microalbumin 9 reagent strips for the early detection and monitoring of kidney disease (discontinued)
In development [GID-MT163] Expected publication date: TBC
-
Microthane implants for breast reconstruction or breast augmentation (discontinued)
In development [GID-MT267] Expected publication date: TBC
-
SILK artery reconstruction device (discontinued)
In development [GID-MT81] Expected publication date: TBC
-
DHT pilot: DECODE decision support system for the identification of dementia (Discontinued)
In development [GID-MT536] Expected publication date: TBC
-
Pembrolizumab for gastric or gastroesophageal junction adenocarcinoma ID1305
In development [GID-TA10244] Expected publication date: TBC
-
Dabrafenib with trametinib for treating advanced, metastatic BRAF V600E mutation-positive non-small-cell lung cancer [ID929]
In development [GID-TA10121] Expected publication date: TBC
-
Durvalumab for treating recurrent or metastatic squamous cell head and neck cancer after platinum-based chemotherapy [ID1231]
In development [GID-TA10473] Expected publication date: TBC
-
Nivolumab with ipilimumab for treating squamous cell carcinoma of the head and neck ID1355
In development [GID-TA10321] Expected publication date: TBC
-
Venetoclax with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma ID1565
In development [GID-TA10502] Expected publication date: TBC
-
Nintedanib for previously treated metastatic colorectal cancer [ID1030]
In development [GID-TA10138] Expected publication date: TBC
-
Nivolumab for treating relapsed or refractory diffuse large B-cell lymphoma [ID986]
In development [GID-TA10140] Expected publication date: TBC
-
Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma after autologous stem cell transplant [ID1103]
In development [GID-TA10144] Expected publication date: TBC
-
NGR-TNF for previously treated advanced malignant pleural mesothelioma (ID655)
In development [GID-TA10183] Expected publication date: TBC
-
Nivolumab for treating recurrent glioblastoma [ID998]
In development [GID-TA10126] Expected publication date: TBC
-
Multiple sclerosis (primary-progressive) - fingolimod [ID62]
In development [GID-TAG221] Expected publication date: TBC
-
Pelareorep for treating recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer [ID1099]
In development [GID-TA10688] Expected publication date: TBC
-
NBTXR-3 for treating soft tissue sarcoma [ID1050]
In development [GID-TA10226] Expected publication date: TBC
-
L-glutamine for preventing painful crises in sickle cell disease in people aged 5 years and over [ID1523]
In development [GID-TA10452] Expected publication date: TBC
-
Nivolumab monotherapy for non-small-cell lung cancer [ID1088]
In development [GID-TA10148] Expected publication date: TBC
-
Nivolumab with radiation therapy for untreated glioblastoma ID1562
In development [GID-TA10443] Expected publication date: TBC
-
Nivolumab in combination with platinum-doublet chemotherapy for untreated non-small-cell lung cancer (ID1135)
In development [GID-TA10233] Expected publication date: TBC
-
Brentuximab vedotin for untreated advanced Hodgkin lymphoma [1258]
In development [GID-TA10224] Expected publication date: TBC
-
Atezolizumab with cobimetinib for untreated BRAF wild-type metastatic melanoma ID1470
In development [GID-TA10354] Expected publication date: TBC
-
Crizotinib for treating metastatic c-MET exon 14-positive non-small-cell lung cancer [ID1472]
In development [GID-TA10625] Expected publication date: TBC
-
Ublituximab with ibrutinib for previously treated chronic lymphocytic leukaemia [ID1476]
In development [GID-TA10447] Expected publication date: TBC